Miromatrix Medical (NASDAQ:MIRO – Get Rating) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Earnings and Valuation
This table compares Miromatrix Medical and BioCryst Pharmaceuticals’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Miromatrix Medical | $950,000.00 | 44.43 | -$29.96 million | ($1.45) | -1.07 |
| BioCryst Pharmaceuticals | $270.83 million | 6.04 | -$247.12 million | ($1.33) | -6.53 |
Miromatrix Medical has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Miromatrix Medical, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Analyst Ratings
This is a breakdown of current recommendations and price targets for Miromatrix Medical and BioCryst Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Miromatrix Medical | 0 | 0 | 1 | 0 | 3.00 |
| BioCryst Pharmaceuticals | 0 | 4 | 5 | 0 | 2.56 |
Miromatrix Medical currently has a consensus target price of $6.00, indicating a potential upside of 287.10%. BioCryst Pharmaceuticals has a consensus target price of $15.78, indicating a potential upside of 81.77%. Given Miromatrix Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Miromatrix Medical is more favorable than BioCryst Pharmaceuticals.
Institutional & Insider Ownership
16.9% of Miromatrix Medical shares are owned by institutional investors. Comparatively, 79.1% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.9% of Miromatrix Medical shares are owned by company insiders. Comparatively, 5.0% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Miromatrix Medical and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Miromatrix Medical | -3,143.76% | -74.77% | -63.20% |
| BioCryst Pharmaceuticals | -91.25% | N/A | -46.04% |
Summary
BioCryst Pharmaceuticals beats Miromatrix Medical on 9 of the 14 factors compared between the two stocks.
About Miromatrix Medical
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
